Compass Therapeutics, Inc. (CMPX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$2.38+0.42%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · CMPX
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Progress clinical trials for tovecimig and other pipeline candidates, including FDA feedback and data presentations.
Stated as a priority in 3 of last 3 quarters. Clinical data for tovecimig showed an overall response rate improvement from 17.1% to 18.0% and progression-free survival of 4.7 months versus 2.6 months for control. Management has consistently emphasized advancing clinical development and FDA engagement, and the trajectory is delivering with ongoing data presentations and planned BLA filing.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 0 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 28% of the time over the next year (vs 52% for the rest of the cohort, n=10029).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“We are increasingly encouraged by the strength and consistency of the tovecimig data as we deepen our analyses ahead of engaging FDA later this month.”
“We recently announced positive data from our Phase 2/3 study of tovecimig and look forward to meeting with the FDA before filing a BLA later this year.”
“We are updating our guidance on the secondary endpoint analyses to Q1 2026.”
Ensure financial resources are adequate to support operations through 2028 without additional funding.
Stated as a priority in 3 of last 3 quarters. Cash and marketable securities decreased from $195 million in 2026-Q1 to $180 million in 2026-Q2, but management expects this to fund operations into 2028. The trajectory is consistent with management's stated cash runway goal.
“$180 million in cash and marketable securities at the end of Q2 2026, expected to fund operations into 2028.”
“$195 million in cash and marketable securities at Q1 2026, expected to fund operations into 2028.”
“The Company expects its cash and cash equivalents will be sufficient to fund its operating expenses into 2028.”
Manage operating expenses and net losses to sustain financial health and extend cash runway.
Stated as a priority in 3 of last 3 quarters. Net loss increased from $19.9 million in 2025-Q2 to $25.2 million in 2026-Q2, driven by higher R&D and G&A expenses related to clinical and pre-commercialization activities. Management continues to monitor operating losses and cash burn, but losses have increased, indicating limited progress in cost control.
“Net loss for the quarter ended June 30, 2026, was $25.2 million compared to $19.9 million for the same period in 2025.”
“Net loss for the quarter ended March 31, 2026, was $18.3 million compared to $16.6 million for the same period in 2025.”
“Operating loss was $17.99 million for Q4 2025 compared to prior periods.”
Over the trailing year it converted 0.96x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
2 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated stable grew net income 46% of the time over the next year (vs 53% for the rest of the cohort, n=3872).
Not investment advice. As of 2026-09-04.